Overview
flowchart TD
companies_dong_a_st["Dong-A ST"]
style companies_dong_a_st fill:#4fc3f7,stroke:#333,color:#000
companies_dong_a_st_0["Company Overview"]
companies_dong_a_st -->|"includes"| companies_dong_a_st_0
style companies_dong_a_st_0 fill:#81c784,stroke:#333,color:#000
companies_dong_a_st_1["Business Segments"]
companies_dong_a_st -->|"includes"| companies_dong_a_st_1
style companies_dong_a_st_1 fill:#ef5350,stroke:#333,color:#000
companies_dong_a_st_2["Pharmaceuticals"]
companies_dong_a_st -->|"includes"| companies_dong_a_st_2
style companies_dong_a_st_2 fill:#ffd54f,stroke:#333,color:#000
companies_dong_a_st_3["Biosimilars"]
companies_dong_a_st -->|"includes"| companies_dong_a_st_3
style companies_dong_a_st_3 fill:#ce93d8,stroke:#333,color:#000
companies_dong_a_st_4["Advanced Drug Delivery"]
companies_dong_a_st -->|"includes"| companies_dong_a_st_4
style companies_dong_a_st_4 fill:#4fc3f7,stroke:#333,color:#000
companies_dong_a_st_5["Neurodegeneration Pipeline"]
companies_dong_a_st -->|"includes"| companies_dong_a_st_5
style companies_dong_a_st_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Dong-A ST Co., Ltd. is a South Korean pharmaceutical company headquartered in Goyang, Gyeonggi Province, South Korea, specializing in novel pharmaceuticals, biosimilars, and advanced drug delivery systems for CNS disorders and other therapeutic areas["@donga"]. The company is a subsidiary of Dong-A Pharmaceutical Co., Ltd., one of Korea's oldest and most established pharmaceutical companies, with a history dating back to 1932.
Company Overview
| Attribute | Value |
|-----------|-------|
| Founded | 1932 (original company) |
| Headquarters | Goyang, Gyeonggi Province, South Korea |
| Parent | Dong-A Pharmaceutical Co., Ltd. |
| Stock | KRX: 170900 |
| Website | donga-st.co.kr |
| Employees | 1,500+ |
| Focus Areas | CNS, oncology, cardiovascular, immunology |
Business Segments
Pharmaceuticals
Dong-A ST focuses on developing and marketing innovative medicines across multiple therapeutic areas:
- Central Nervous System (CNS): Parkinson's disease, Alzheimer's disease, depression, epilepsy
- Oncology: Targeted therapies, biosimilars
- Cardiovascular: Antihypertensives, antiplatelets
- Immunology: Autoimmune diseases, inflammation
Biosimilars
The company has invested significantly in biosimilar development:
- Monoclonal antibody biosimilars for oncology and autoimmune diseases
- Cost-competitive alternatives to originator biologics
- Global market access through partnerships
Advanced Drug Delivery
Dong-A ST maintains advanced drug delivery platforms:
- Novel Drug Delivery System (NDDS): Extended-release formulations
- Transdermal systems: Patch technology for CNS drugs
- nanoparticle formulations: Enhanced bioavailability
Neurodegeneration Pipeline
Parkinson's Disease Programs
| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| DA-3501 | Long-acting dopamine agonist | Phase 2 | Active |
| DA-3201 | COMT inhibitor | Phase 1 | Completed |
| DA-4001 | Alpha-synuclein antibody | Discovery | Research |
DA-3501 is the company's lead Parkinson's program—a novel long-acting dopamine agonist designed to provide extended symptom control with reduced dosing frequency. The Phase 2 program is actively recruiting patients to evaluate efficacy and safety.
DA-3201 is a COMT (catechol-O-methyltransferase) inhibitor that works alongside levodopa to extend its duration of action. Phase 1 studies have been completed, demonstrating safety and tolerability.
DA-4001 represents Dong-A ST's entry into disease-modifying Parkinson's therapy—an alpha-synuclein antibody targeting the pathological protein aggregation seen in Parkinson's disease.
Alzheimer's Disease Programs
| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| DA-4501 | Amyloid-beta antibody | Phase 1 | Recruiting |
| DA-4601 | Neuroprotective agent | Preclinical | Research |
DA-4501 is an amyloid-beta targeting monoclonal antibody in Phase 1 clinical trials, designed to reduce amyloid plaque burden in Alzheimer's disease patients.
DA-4601 is a neuroprotective agent in preclinical development, targeting multiple pathways involved in neuronal survival and function.
Key Products
Existing CNS Portfolio
| Product | Indication | Description |
|---------|------------|-------------|
| Tremycin | Parkinson's disease | Levodopa/carbidopa combination therapy |
| Duxenil | Cognitive enhancement | Nootropic agent for memory and cognition |
| Stelaton | Parkinson's disease | Dopamine agonist for motor symptoms |
Other Therapeutic Areas
- Oncology: Generic and biosimilar oncology drugs
- Cardiovascular: Antihypertensive and antiplatelet medications
- Gastrointestinal: Acid-related disease treatments
- Dermatology: Topical formulations
Novel Drug Delivery System (NDDS)
Dong-A ST's NDDS platform enables:
- Extended-release formulations reducing dosing frequency
- Improved patient compliance
- Controlled drug release for optimized efficacy
- Novel formulation technologies for challenging molecules
Biosimilar Development
The company has established biosimilar capabilities:
- Monoclonal antibody biosimilar development
- Analytical characterization matching originator products
- Clinical development for global registration
- Manufacturing scale-up capabilities
Regenerative Medicine
Research into cell therapy approaches:
- Stem cell-based therapies for neurological disorders
- Gene therapy vectors
- Cell culture and manufacturing expertise
Global Partnerships
Dong-A ST has established international collaborations to expand market access and enhance R&D capabilities:
| Partner | Focus Area |
|---------|------------|
| Pfizer | Licensing agreement for selected products |
| Merck KGaA | Distribution partnership in select markets |
| Seoul National University | Academic research collaboration |
| Yonsei University | Clinical research partnership |
International Expansion
The company actively pursues global market expansion:
- Asia-Pacific: Strong presence in Korea, Japan, and Southeast Asia
- Middle East: Registration and distribution partnerships
- Latin America: Market access through local partners
- Europe: Strategic partnerships for biosimilar commercialization
Manufacturing Capabilities
Dong-A ST maintains sophisticated manufacturing facilities:
- Oral solid dosage: Tablets, capsules, granules
- Parenteral: Injectables, IV formulations
- Biologics: Biosimilar manufacturing capabilities
- Transdermal: Patch manufacturing for CNS drugs
All facilities comply with international GMP standards (FDA, EMA, Korean MFDS).
Market Position
In Korea
Dong-A ST is recognized as one of Korea's leading pharmaceutical companies:
- Top 10 Korean pharmaceutical companies by revenue
- Strong market position in CNS therapeutics
- Established brand recognition among healthcare professionals
Competitive Advantages
Research pipeline: Innovative CNS drugs in development
Manufacturing quality: GMP-compliant facilities
Market access: Established distribution networks
Partnerships: Strategic alliances with global companies
Heritage: Long-standing reputation in Korean pharmaFuture Directions
Near-Term Priorities
- Complete Phase 2 trials for DA-3501 in Parkinson's disease
- Advance DA-4501 through Phase 1 clinical development
- Expand biosimilar portfolio in oncology and immunology
Long-Term Vision
- Become a leading CNS-focused pharmaceutical company in Asia
- Develop disease-modifying therapies for neurodegenerative diseases
- Expand global presence through partnerships and direct market access
Related Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Korea Neurodegeneration Companies](/companies/korea-neurodegeneration-companies)
- [Asian Pharmaceutical Companies](/companies/asian-pharmaceutical-neurodegeneration)
- [Dopamine Agonists](/therapeutics/dopamine-agonists)
- [COMT Inhibitors](/therapeutics/comt-inhibitors)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Korean Biotech Companies](/companies/korea-biotech)
References
[Dong-A ST Corporate Website](https://www.donga-st.co.kr)
[Dong-A Pharmaceutical Group](https://www.donga.co.kr)
[Korean Pharmaceutical Industry Report (2023)](https://www.kpanet.or.kr/)